372 related articles for article (PubMed ID: 12925698)
21. Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.
Aykul S; Parenti A; Chu KY; Reske J; Floer M; Ralston A; Martinez-Hackert E
J Biol Chem; 2017 Mar; 292(10):4138-4151. PubMed ID: 28126904
[TBL] [Abstract][Full Text] [Related]
22. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
[TBL] [Abstract][Full Text] [Related]
23. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
24. Cripto promotes A-P axis specification independently of its stimulatory effect on Nodal autoinduction.
D'Andrea D; Liguori GL; Le Good JA; Lonardo E; Andersson O; Constam DB; Persico MG; Minchiotti G
J Cell Biol; 2008 Feb; 180(3):597-605. PubMed ID: 18268105
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.
Danila DC; Zhang X; Zhou Y; Haidar JN; Klibanski A
J Clin Endocrinol Metab; 2002 Oct; 87(10):4741-6. PubMed ID: 12364468
[TBL] [Abstract][Full Text] [Related]
26. Nodal and Cripto-1: embryonic pattern formation genes involved in mammary gland development and tumorigenesis.
Kenney NJ; Adkins HB; Sanicola M
J Mammary Gland Biol Neoplasia; 2004 Apr; 9(2):133-44. PubMed ID: 15300009
[TBL] [Abstract][Full Text] [Related]
27. Structural investigations on the Nodal-Cripto binding: a theoretical and experimental approach.
Calvanese L; Marasco D; Doti N; Saporito A; D'Auria G; Paolillo L; Ruvo M; Falcigno L
Biopolymers; 2010 Nov; 93(11):1011-21. PubMed ID: 20629020
[TBL] [Abstract][Full Text] [Related]
28. Role of human cripto-1 in tumor angiogenesis.
Bianco C; Strizzi L; Ebert A; Chang C; Rehman A; Normanno N; Guedez L; Salloum R; Ginsburg E; Sun Y; Khan N; Hirota M; Wallace-Jones B; Wechselberger C; Vonderhaar BK; Tosato G; Stetler-Stevenson WG; Sanicola M; Salomon DS
J Natl Cancer Inst; 2005 Jan; 97(2):132-41. PubMed ID: 15657343
[TBL] [Abstract][Full Text] [Related]
29. Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway.
Shi Y; Bao YL; Wu Y; Yu CL; Huang YX; Sun Y; Zheng LH; Li YX
J Biomol Screen; 2011 Jun; 16(5):525-35. PubMed ID: 21378277
[TBL] [Abstract][Full Text] [Related]
30. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells.
Normanno N; De Luca A; Bianco C; Maiello MR; Carriero MV; Rehman A; Wechselberger C; Arra C; Strizzi L; Sanicola M; Salomon DS
J Cell Physiol; 2004 Jan; 198(1):31-9. PubMed ID: 14584041
[TBL] [Abstract][Full Text] [Related]
31. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments.
Calvanese L; Sandomenico A; Caporale A; Focà A; Focà G; D'Auria G; Falcigno L; Ruvo M
J Pept Sci; 2015 Apr; 21(4):283-93. PubMed ID: 25588905
[TBL] [Abstract][Full Text] [Related]
32. An evolving web of signaling networks regulated by Cripto-1.
Nagaoka T; Karasawa H; Castro NP; Rangel MC; Salomon DS; Bianco C
Growth Factors; 2012 Feb; 30(1):13-21. PubMed ID: 22149969
[TBL] [Abstract][Full Text] [Related]
33. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development.
Reissmann E; Jörnvall H; Blokzijl A; Andersson O; Chang C; Minchiotti G; Persico MG; Ibáñez CF; Brivanlou AH
Genes Dev; 2001 Aug; 15(15):2010-22. PubMed ID: 11485994
[TBL] [Abstract][Full Text] [Related]
34. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.
Focà A; Sanguigno L; Focà G; Strizzi L; Iannitti R; Palumbo R; Hendrix MJ; Leonardi A; Ruvo M; Sandomenico A
Int J Mol Sci; 2015 Sep; 16(9):21342-62. PubMed ID: 26370966
[TBL] [Abstract][Full Text] [Related]
35. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
Baldassarre G; Bianco C; Tortora G; Ruggiero A; Moasser M; Dmitrovsky E; Bianco AR; Ciardiello F
Int J Cancer; 1996 May; 66(4):538-43. PubMed ID: 8635871
[TBL] [Abstract][Full Text] [Related]
36. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Kelber JA; Panopoulos AD; Shani G; Booker EC; Belmonte JC; Vale WW; Gray PC
Oncogene; 2009 Jun; 28(24):2324-36. PubMed ID: 19421146
[TBL] [Abstract][Full Text] [Related]
37. Two modes by which Lefty proteins inhibit nodal signaling.
Chen C; Shen MM
Curr Biol; 2004 Apr; 14(7):618-24. PubMed ID: 15062104
[TBL] [Abstract][Full Text] [Related]
38. EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1.
Cheng SK; Olale F; Bennett JT; Brivanlou AH; Schier AF
Genes Dev; 2003 Jan; 17(1):31-6. PubMed ID: 12514096
[TBL] [Abstract][Full Text] [Related]
39. Nodal signaling uses activin and transforming growth factor-beta receptor-regulated Smads.
Kumar A; Novoselov V; Celeste AJ; Wolfman NM; ten Dijke P; Kuehn MR
J Biol Chem; 2001 Jan; 276(1):656-61. PubMed ID: 11024047
[TBL] [Abstract][Full Text] [Related]
40. Chemical synthesis of mouse cripto CFC variants.
Marasco D; Saporito A; Ponticelli S; Chambery A; De Falco S; Pedone C; Minchiotti G; Ruvo M
Proteins; 2006 Aug; 64(3):779-88. PubMed ID: 16752415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
